LUND, Sweden, Nov. 26, 2019 /PRNewswire/ -- Camurus announced today topline results from the 24-week, randomized, controlled, open-label, DEBUT study of weekly and monthly Buvidal (®) (prolonged ...

Camurus (NASDAQ: CAMX) (STO: CAMX) today announced positive, final, topline results from the 52-week Phase 3 open-label ACROINNOVA 2 (NCT04125836) study, which evaluated safety and efficacy of the ...

Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions.

--Camurus today announced topline results from the 12- month, randomized, double-blind, placebo-controlled POSITANO Phase 2 b study, evaluating efficacy and safety of octreotide subcutaneous depot ...

Camurus boosted investment sharply in the last year, with cash burn ramping by 57%. While that certainly give us pause, we take a lot of comfort in the strong annual revenue growth of 67%.

Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty "We are pleased to enter into this collaboration with Lilly to ...

Camurus maintained its full-year 2025 guidance, projecting revenue between SEK 2.7-3.0 billion (45-61% growth versus 2024) and profit before tax of SEK 0.9-1.2 billion (63-117% growth versus 2024).

Camurus AB will release earnings for the most recent quarter on May 12. Analysts are expecting losses per share of SEK 0.219. Go here to follow Camurus AB stock price in real-time ahead of earnings.

Camurus AB (STO:CAMX) presented its second quarter 2025 results on July 17, revealing record financial performance and significant progress across its product portfolio. The Swedish specialty ...

Rhythm will use Camurus' drug delivery technology, FluidCrystal ®, to formulate its once-weekly obesity drug candidate, setmelanotide (RM-493), then develop, manufacture, and commercialize the ...

Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX.

Camurus delivered exceptional financial results in Q1 2025, with total revenue reaching SEK 558 million, representing a 43% increase year-over-year. The company achieved record-high profitability with ...